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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized 
by resistance to currently employed chemotherapeutic approaches. Members of the 
mir-17~92 cluster of microRNAs (miRNAs) are upregulated in PDAC, but the precise 
roles of these miRNAs in PDAC are unknown. Using genetically engineered mouse 
models, we show that loss of mir-17~92 reduces ERK pathway activation downstream 
of mutant KRAS and promotes the regression of KRASG12D-driven precursor pancreatic 
intraepithelial neoplasias (PanINs) and their replacement by normal exocrine tissue. 
In a PDAC model driven by concomitant KRASG12D expression and Trp53 heterozygosity, 
mir-17~92 deficiency extended the survival of mice that lacked distant metastasis. 
Moreover, mir-17~92-deficient PDAC cell lines display reduced invasion activity in 
transwell assays, form fewer invadopodia rosettes than mir-17~92-competent cell 
lines and are less able to degrade extracellular matrix. Specific inhibition of miR-19  
family miRNAs with antagomirs recapitulates these phenotypes, suggesting that  
miR-19 family miRNAs are important mediators of PDAC cell invasion. Together these 
data demonstrate an oncogenic role for mir-17~92 at multiple stages of pancreatic 
tumorigenesis and progression; specifically, they link this miRNA cluster to ERK 
pathway activation and precursor lesion maintenance in vivo and identify a novel 
role for miR-19 family miRNAs in promoting cancer cell invasion. 
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is 
the most common and the deadliest form of pancreatic 
cancer, comprising 85% of all cases, with a five-year 
survival rate of just 6.7% [1, 2]. PDAC commonly arises 
from precancerous lesions called pancreatic intraepithelial 
neoplasias (PanINs) [3]. These lesions are characterized by 
very high occurrence of mutations in the KRAS oncogene 
that are also maintained throughout disease progression 
and found in over 90% of PDAC cases [4]. These findings 
indicate that KRAS could be a robust therapeutic target in 
PDAC. Indeed, murine pancreatic cancers with activated 
KRAS (e.g. KRASG12D and KRASG12V) exhibit oncogene 
addiction, whereby suppression of KRAS activity induces 
cell death in advanced tumors and regression of early 
PanINs [5–7]. However, efforts to directly inhibit KRAS 
activity in human tumors have thus far been unsuccessful 
[8]. Moreover, clinical and preclinical studies have 
demonstrated the complexities of inhibiting the well-
characterized downstream RAF/MEK/ERK and PI3K/
AKT pathways [9–14]. These findings highlight the 
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complexity of the signaling networks downstream of 
activated KRAS and suggest potential roles for post-
transcriptional mechanisms that may buffer signaling 
downstream of KRAS. Therefore, a deeper understanding 
of the factors that influence KRAS-driven tumor initiation 
and progression in the pancreas is greatly needed.
MicroRNAs (miRNAs) are highly conserved 
short non-coding RNAs that influence gene expression 
post-transcriptionally and regulate development, normal 
physiology and disease [15]. MiRNAs have been 
demonstrated to regulate the initiation and progression 
of many malignancies by controlling oncogenic and 
tumor suppressive pathways [16]. Among the earliest 
described oncogenic miRNAs were members of the 
mir-17~92 cluster [17, 18]. mir-17~92 has been implicated 
in a variety of cancer contexts [19], and inhibition 
of members of this cluster has been shown to impair 
tumor growth and survival [20, 21]. Profiling of human 
pancreatic tumors and pancreatic cancer cell lines has 
shown that miRNAs encoded by the mir-17~92 cluster 
and its paralogs–mir-106b~25 and mir-106a~363–are 
upregulated in tumors compared to normal pancreatic 
tissue or chronic pancreatitis [22, 23]. In addition, 
mir-17~92-encoded miRNAs are induced in precursor 
PanIN lesions, implicating them in early stages of PDAC 
development [24], and miR-17 overexpression has been 
associated with reduced pancreatic cancer patient survival 
[25]. The mir-17~92 cluster was initially identified as 
oncogenic over a decade ago [18, 26]. Subsequent studies 
have demonstrated critical roles for this microRNA cluster 
in several malignancies including B-cell lymphoma, 
retinoblastoma, medulloblastoma, hepatocellular 
carcinoma and neuroblastoma [20, 21, 27–34]. Individual 
miRNAs within the cluster have been associated with 
specific tumorigenic properties. Of note, the miR-19 
microRNAs have been associated with tumor cell invasion 
and metastasis in gastric cancer [35], lung cancer [36] and 
colon cancer [37]. 
Studies in pancreatic cancer cell lines additionally 
demonstrated roles for the mir-17~92 cluster in PDAC cell 
proliferation, transformation and invasion [25, 38, 39]. 
However, to date no studies have been performed to 
evaluate the role of the cluster in vivo during pancreatic 
tumor initiation and progression. Given the upregulation 
of these miRNAs in human pancreatic cancers and their 
validated role as oncogenes in a variety of contexts, we 
hypothesized that they contribute to KRAS-induced 
pancreatic tumorigenesis. Therefore, we experimentally 
tested the requirement for mir-17~92 in a mouse model of 
pancreatic cancer.
We find that deletion of mir-17~92 impairs MEK/ERK 
signaling in PanIN lesions and this correlates with the 
presence of fewer PanINs, as well as their regression over 
time. In addition, we find that mir-17~92 miRNAs, in 
particular miR-19 family miRNAs, promote PDAC cell 
invasion by regulating the formation of extracellular matrix-
degrading invadopodia rosettes. Together, these findings 
illustrate important roles for mir-17~92 miRNAs during 
multiple phases of PDAC development and progression.
RESULTS
mir-17~92 loss does not impact normal pancreas 
development
 Prior miRNA expression profiling studies of human 
PDAC specimens demonstrated elevated expression of 
components of the mir-17~92 cluster in PDAC. However, 
the results from these studies were somewhat inconsistent, 
potentially reflecting the significant stromal and immune 
cell component of pancreatic tumors. To ascertain whether 
mir-17~92 miRNAs have elevated expression in PDAC 
cells, we profiled a panel of PDAC cell lines as well as the 
immortalized pancreatic epithelial cell line HPNE. We find 
that mir-17~92 miRNAs are consistently overexpressed 
in PDAC cell lines (Supplementary Figure 1). Thus, we 
set out to identify the role of this microRNA cluster in 
pancreatic tumorigenesis in vivo in genetically engineered 
mouse models.
To determine the effect of mir-17~92 loss on 
pancreatic development, we induced pancreas-specific 
deletion of the mir-17~92 cluster using the conditional 
mir-17~92flox allele and the recombination driver Ptf1a-Cre 
[40, 41]. qRT-PCR of RNA from whole pancreata showed 
a strong reduction in the levels of mir-17~92 constituent 
miRNAs in compound mir-17~92flox/flox, Ptf1a-Cre mice 
(Supplementary Figure 2A). The observed residual 
 mir-17~92 expression is likely from endocrine cells, many 
of which are derived from a PTF1A-independent lineage 
[40, 42], as well as a small population of acinar and ductal 
cells that have avoided recombination due to the fact 
that Cre drivers are not 100% efficient [43]. Expression 
from the paralogous mir-106b~25 cluster is unaffected 
(Supplementary Figure 2A). Despite efficient depletion 
of mir-17~92 miRNAs from the pancreas, organ size and 
exocrine and endocrine architecture and composition were 
unperturbed (Supplementary Figure 2B). These findings 
demonstrate that mir-17~92 is not required for normal 
pancreas development.
mir-17~92 loss promotes PanIN loss and exocrine 
recovery
To assess the impact of mir-17~92 deletion on the 
development and progression of precursor precancerous 
PanIN lesions, we crossed mir-17~92flox/flox, Ptf1a-Cre mice 
onto the LSL-KrasG12D background [44]. Breeding pairs 
were designed to cross mir-17~92flox/wt, LSL-KrasG12D mice 
with mir-17~92flox/wt, Ptf1a-Cre mice in order to generate 
littermate mir-17~92wt/wt, LSL-KrasG12D, Ptf1a-Cre and 
mir-17~92flox/flox, LSL-KrasG12D, Ptf1a-Cre mice (hereafter 
‘KC’ and ‘17KC’). Littermate KC and 17KC animals 
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were maintained until four or nine months of age and 
subsequently euthanized to obtain pancreata for histological 
analysis. At four months of age, the tissue area occupied 
by PanIN lesions was not significantly different between 
the two groups as illustrated by hematoxylin and eosin 
staining and quadchrome staining (Figure 1A–1D, 1I). 
However, the extent of normal acinar tissue was 
significantly greater in the pancreata of 17KC mice 
(Figure 1I). Nine month-old KC mice displayed higher 
PanIN burdens compared to younger KC mice and nine 
month-old 17KC littermates (Figure 1E–1I). In contrast 
to the trend observed in KC mice, we observed that the 
pancreata of nine month-old 17KC mice exhibited less 
PanIN tissue and more healthy acinar tissue by area than 
four month-old 17KC mice (Figure 1F, 1H, 1I). Of note, 
PanIN lesions in KC and 17KC pancreata demonstrate no 
significant differences in proliferation or apoptosis markers 
and no differences were observed in the proliferative 
rate of adjacent acinar tissue (Supplementary Figure 3). 
Together, these data suggest that loss of mir-17~92 impairs 
the maintenance of PanIN lesions.
Recent work suggested that inhibition of MEK/
ERK signaling promotes the regression of PanIN lesions 
[45]. As determined by immunohistochemical staining for 
phosphorylated ERK, we observed that 17KC PanINs display 
marked reduction in MAPK signaling (Figure 2A–2D). 
In contrast to the difference in phosphorylated ERK, 
phosphorylation of the upstream kinase MEK was not 
different between the two genotypes, suggesting that 
signaling through the MEK/ERK cascade is impacted at 
the level of ERK but not further upstream (Figure 2E–2H). 
Moreover, ectopic mir-17~92 expression in murine PanIN 
cell lines [46, 47] increased p-ERK levels under both serum 
replete and serum starved conditions (Figure 3A, 3B), 
confirming that mir-17~92-encoded miRNAs regulate 
this pathway.
Analysis of the phosphorylation status of AKT 
at the Thr308 and Ser473 sites that are phosphorylated by 
PDK1 and mTORC2 also did not show any differences 
between genotypes (Figure 2I–2P). Taken together with 
the phosphorylation of MEK, these data suggest that 
the alterations in ERK phosphorylation do not reflect 
an overall reduction in KRAS signaling, and further 
suggest that mir-17~92 regulates PanIN maintenance by 
specifically influencing ERK pathway activity downstream 
of KRASG12D and MEK. 
We utilized the TargetScan database [48] to identify 
known and putative mRNA targets of mir-17~92 that are 
implicated in the regulation of ERK phosphorylation. 
We identified the dual specificity phosphatases DUSP2, 
DUSP7 and DUSP10, which are known to regulate MAP 
kinase phosphorylation, as potential targets of cluster-
encoded miRNAs [49, 50]. However, immunostaining of 
PanIN lesions with antibodies against these phosphatases 
did not show any differences between mir-17~92 wild 
type and deficient PanINs (data not shown). Moreover, 
the enhanced ERK phosphorylation observed in PanIN 
cell lines following ectopic mir-17~92 expression was 
not associated with changes in DUSP7 or DUSP10 
protein levels (Supplementary Figure 4). DUSP2 was 
undetectable by immunoblotting or qRT-PCR in these cell 
lines (data not shown). Thus, the detailed mechanisms 
regulating ERK phosphorylation in PanINs downstream of 
mir-17~92 remain unknown.
mir-17~92-deficient tumors display a delayed 
invasion phenotype
To assess whether mir-17~92 deletion impairs 
progression to carcinoma, we accelerated the KC model 
by including conditional loss of one copy of Trp53 (LSL-
KrasG12D, Trp53flox/wt, Ptf1a-Cre and mir-17~92flox/flox, 
LSL-KrasG12D, Trp53flox/wt, Ptf1a-Cre; hereafter “KPC” 
and “17KPC” mice). We observed that KPC and 17KPC 
mice display similar overall survival and tumor size 
(Figure 4A, 4B). Rates of liver metastasis are also 
equivalent between groups (Supplementary Figure 5A, 5B). 
The carcinomas identified in mice of both genotypes 
displayed a mixture of glandular and undifferentiated 
histology; no difference in the relative frequencies of the 
histologic types was identified between the two groups 
(Supplementary Figure 5C–5E). Histological evidence of 
invasion was also equally prevalent in both groups, and 
variously involved the stomach/duodenum, liver, colon, and 
spleen (Supplementary Figure 5F–5J). The histopathology 
findings are summarized in Supplementary Table 1. 
Additionally, tumors across both groups exhibited similar 
rates of proliferation and apoptosis as demonstrated by 
Ki67 and cleaved caspase 3 (CC3) staining (Supplementary 
Figure 6). Moreover, KPC and 17KPC tumors display 
equivalent MEK/ERK pathway activation as measured by 
immunostaining for phosphorylated ERK (Supplementary 
Figure 7A, 7B). Further, cell lines derived from KPC 
and 17KPC tumors display similar levels of ERK 
phosphorylation and similar levels of DUSP7 and DUSP10 
expression (Supplementary Figure 7C, 7D). Together, 
these findings suggest that heterozygous deletion of Trp53 
compensates for the loss of mir-17~92 and promotes 
disease progression in mir-17~92 deficient animals. 
In the KPC mouse model, mice reliably generate 
aggressive primary tumors that invade adjacent tissues and 
sporadically metastasize: thus, morbidity and euthanasia 
result from the effects of either the primary tumor or its 
metastases. To ascertain whether mir-17~92 deletion 
differentially impacted primary versus metastatic disease 
processes, we stratified survival data based on the presence 
or absence of grossly visible metastases at euthanasia. 
The majority of KPC mice lacked metastases and were 
sacrificed at relatively young ages due to effects of the 
primary tumor (“localized” mice), whereas a minority 
presented later with metastatic disease (“metastatic 
mice”) (Figure 4C), suggesting that primary KPC tumors 
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Figure 1: mir-17~92 null PanINs regress with age. Histological evaluation of PanIN lesions in pancreata from 4-month old 
(A–D) and 9-month old (E–H) KC and 17KC mice. Representative images from hematoxylin and eosin (A, B, E, F) and quadchrome 
(simultaneous Alcian Blue and Sirius Red staining; C–H ) stains are shown. (I) Quantification of normal and neoplastic cell types as a 
percentage of total tissue area. The quadchrome stain marks collagen red, mucin blue, cytoplasm yellow-brown, and nucleic acids black. 
Arrowheads identify examples of PanIN lesions. Ac = Acinar tissue. Number of organs (n) analyzed for each group were 4 mo KC (4), 
4 mo 17KC (7), 9 mo KC (3), 9 mo 17KC (2). Scale bar = 0.25 mm. p values by Student’s t test: * < 0.05, ** < 0.01. Error bars represent 
standard deviation from the mean.
Oncotarget35906www.impactjournals.com/oncotarget
cause significant morbidity prior to the development of 
metastases. However, this was not observed in 17KPC 
mice, where localized and metastatic mice display 
similar survival curves (Figure 4D). Indeed, the survival 
of metastatic mice is not significantly different between 
KPC and 17KPC mice (data not shown), but the survival 
of localized KPC mice was significantly worse than that 
of localized 17KPC mice (Figure 4E). Moreover, localized 
17KPC mice also possessed larger tumors than localized 
KPC mice (Figure 4F).  Together, these data suggest that 
mir-17~92 contributes to the morbidity and mortality 
caused by primary KPC tumors and does not impact time 
to metastasis. 
The observed differences in survival among animals 
with localized disease could be the result of reduced or 
delayed invasive potential of 17KPC primary tumors. 
Thorough histological step sectioning of all primary tumors 
and adjacent tissues obtained in the study demonstrated 
equivalent evidence of invasion between KPC and 17KPC 
animals at the time of euthanasia (data not shown). This 
suggests that local invasion is a common endpoint in 
our survival study, but requires more time to develop in 
17KPC mice, resulting in the longer survival and larger 
tumors of localized 17KPC mice compared to localized 
KPC mice. Localized pancreatic cancer in mice can cause 
morbidity with biliary obstruction and jaundice (evident 
in the ears, footpads, or pancreas) or gastrointestinal (GI) 
obstruction, as seen by gross abdominal distension and 
GI lumen distension upstream of an adhesion with the 
absence of downstream luminal contents on necropsy. 
While these features were commonly observed in KPC 
mice, 17KPC mice never presented with any form of GI 
or biliary obstruction (Supplementary Figure 8). Other 
characteristics of tumor presentation such as the presence 
of adhesions to adjacent organs, intraperitoneal bleeding, 
jaundice or ascites demonstrated no significant differences 
between KPC and 17KPC mice (Supplementary Figure 8). 
Together, these in vivo findings suggest that loss of the 
mir-17~92 cluster may impact PDAC cell invasion, a 
feature associated with later stages of disease. 
mir-17~92-deficient cell lines are less invasive  
in vitro
 To better understand the biology of mir-17~92 
deficient pancreatic cancer cells, we generated a collection 
of cell lines from KPC and 17KPC tumors. Evaluation 
of cell invasion in transwell assays demonstrated that 
17KPC cell lines have reduced ability to invade through 
Matrigel relative to KPC cell lines (Figure 5A). However, 
no differences were observed between the two genotypes 
in their ability to migrate across uncoated membranes 
Figure 2: mir-17~92 null PanINs display reduced MEK/ERK pathway activation. Immunostaining of PanIN lesions identified 
in 4- and 9-month old KC and 17KC mice for phosphorylated ERK (A–D), phosphorylated MEK (E–H), AKT phosphorylated at Thr308 
(I–L), and AKT phosphorylated at Ser473 (M–P). Scale bar = 0.1 mm.
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Figure 3: ERK signaling is increased by mir-17~92 overexpression in PanIN cell lines. (A) Representative immunoblot 
for pERK and total ERK in the PanIN cell lines RP2294 and AH2375 stably infected with PIG-mir-17~92 or empty vector. (B) Average 
densitometry for three experiments performed in (A). Error bars represent standard deviation from the mean.
Figure 4: Loss of mir-17~92 prolongs survival in mice without metastases. (A) Kaplan-Meier survival plot for KPC and 
17KPC mice. (B) Primary tumor burden identified in these mice upon euthanasia. (C) Kaplan-Meier survival plot comparing metastatic 
and localized KPC mice. (D) Kaplan-Meier survival plot comparing metastatic and localized 17KPC mice. (E) Kaplan-Meier survival plot 
comparing localized KPC and localized 17KPC mice. (F) Total primary tumor burden of localized mice. Number of animals (n) for each 
group were as follows: KPC (18), 17KPC (18), metastatic/localized KPC (5/13), metastatic/localized 17KPC (7/11), female/male KPC 
(7/11), female/male 17KPC (10/8). p values: * < 0.05. Error bars represent standard deviation from the mean.
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(Figure 5B). Additionally, there were no significant 
differences in the proliferation, anchorage independent 
growth, or survival phenotypes of KPC and 17KPC cell 
lines (Figure 5C–5F). These data agree with the suggestion 
that 17KPC tumors display delayed invasion in vivo, and 
suggest a specific defect in the ability of tumor cells to 
manipulate extracellular matrix.
In cancer cells, invasion activity is associated with 
the presence of specific matrix-degrading, cell adhesion 
structures called invadopodia [51, 52]. Invadopodia can 
be identified by the organization of their core cytoskeletal 
protein components–actin and cortactin–into punctate or 
rosette-shaped structures that are functionally associated 
with localized sites of elevated metalloproteinase activity 
[51, 53–55]. To better understand the nature of the 
invasive defect that we observed in 17KPC cell lines, we 
analyzed invadopodia formation by immunofluorescence. 
We found that invadopodia in KPC and 17KPC cell lines 
take the form of rosettes and that KPC cell lines display 
significantly higher rates of invadopodia rosette formation 
Figure 5: mir-17~92 null PDAC cell lines have reduced invasive capacity in vitro. Characterization of in vitro phenotypes of 
PDAC cell lines derived from KPC and 17KPC tumors. (A) Invasion activity in transwell assays, displayed as invasion index [(number of 
invading cells/number of migrating cells) × 100]. (B) Migration activity in transwell assays. (C) Proliferation rate. (D) Colony formation 
in a soft agar. (E) Cell survival in serum-replete medium. (F) Cell survival in serum-free medium. Cell line nomenclature is noted as 
cage#animal# (e.g. 9025#2 is the cell line derived from the primary tumor of mouse #2 from cage #9025). All error bars represent SD. 
p value: * < 0.05.
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than 17KPC lines (Figure 6A–6I). In agreement with 
reduced invadopodia numbers, 17KPC cell lines also 
degrade less FITC-labeled gelatin matrix than KPC lines 
(Figure 6J–6N). These data suggest that loss of mir-17~92 
decreases invasion, at least in part, as a result of reduced 
matrix-degrading capacity.
miR-19 promotes invadopodia formation and the 
invasiveness of pancreatic cancer cell lines
The mir-17~92 cluster encodes six miRNAs 
encompassing four miRNA seed families (Figure 7A), 
implicating thousands of predicted mRNA targets as 
downstream effectors of the cluster’s invasive program. 
To aid in our determination of which miRNA families 
may be most important in the invasive phenotype, we 
evaluated nine KPC and nine 17KPC cell lines for their 
expression of miR-17, -18, -19, and -92 family miRNAs 
across the three cluster paralogs: mir-17~92, mir-106b~25, 
and mir-106a~363. Quantitative RT-PCR demonstrated 
that 17KPC cell lines are indeed null for miRNAs from 
mir-17~92, however they retain robust expression from 
mir-106b~25 (Figure 7B, 7C). In fact, the mir-106b~25 
locus is sufficient to drive expression of miRNAs for 
the miR-17 and miR-92 families to levels close to those 
observed in KPC lines, suggesting that loss of the miR-17 
and -92 families may not be primarily responsible for the 
invasive defect of 17KPC cell lines. In contrast, miR-19 
family miRNAs can only be expressed from the 
mir-17~92 and mir-106a~363 clusters, and 17KPC lines 
were found to completely lack expression of this miRNA 
family (Figure 7E). Based on the partial residual expression 
of the miR-17 and miR-92 families (Figure 7B, 7C), 
and the generally very low expression of the miR-18 
family (Figure 7D, note y axis units), we hypothesized 
that loss of the miR-19 family was responsible for the 
defective invasion of 17KPC cell lines.
To validate that miR-19 family miRNAs play an 
important role in invasion, we utilized antagomirs–short 
oligonucleotides that bind and inactivate miRNAs–to 
Figure 6: mir-17~92 null PDAC cell lines form fewer invadopodia rosettes. Immunofluorescence staining for the invadopodia 
constituent proteins cortactin (A, E), actin (B, F) and paxillin (C, G) in representative KPC and 17KPC cell lines. Merged images are shown 
in (D) and (H). D′ and H′ are higher magnification views of panels D and H. Scale bar = 10 um. Quantification of invadopodia rosettes is 
shown in (I). n = 3 for each cell line. Areas of FITC-gelatin degradation, identified as dark regions, are shown for representative KPC and 
17KPC cell lines (J, L). (K, M) Co-staining for actin and DNA (DAPI). (N) Quantification of gelatin degradation. n = 3 for each cell line. 
Error bars represent standard error of the mean. p values: * < 0.05, ** < 0.01, **** < 0.0001.
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specifically knock down miR-19 function in KPC lines 
with high invasive capacity and varying levels of miR-
19 expression [56]. We first confirmed miR-19 antagomir 
activity using a β-galactosidase (β-Gal) reporter containing 
multiple miR-19 binding sites within the 3’UTR that 
allow translational suppression in the presence of miR-
19. Pooled antagomirs against miR-19a and miR-19b 
enhanced reporter activity in a KPC cell line, but not in a 
17KPC cell line (Supplementary Figure 9).
MiR-19 antagomirs significantly inhibited KPC cell 
line invasion, but not migration, consistent with an invasion-
specific effect for miR-19 family miRNAs (Figure 8A, 8B). 
This response inversely correlated with the level of 
endogenous miR-19 family expression, suggesting a dosage 
response (Figure 8C). Indeed, the cell line with the highest 
expression of miR-19, 9415#2, was resistant to antagomirs 
at a concentration of 50 nM, but responded when treated 
with antagomirs at 100 nM (Figure 8A, 8C). We next 
Figure 7: miR-19 family expression is absent in 17KPC cell lines. (A) Schematic representation of the mir-17~92 cluster and its 
paralogs mir-106b~25 and mir-106a~363. Constituent miRNAs are color-coded according to their seed families. (B–E) Quantitative RT-PCR 
measurement of mature miRNA expression across eighteen cell lines derived from primary KPC and 17KPC tumors. Some miRNAs share 
sufficient sequence similarity that standard oligonucleotides amplify both species equally (e.g. miR-19a and miR-19b), and therefore not 
all miRNAs are individually plotted. p values: **** < 0.0001. Error bars represent standard deviation from the mean.
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ascertained whether miR-19 regulates invasion in human 
PDAC cells. The human pancreatic cancer cell lines MIA 
Paca-2 and PANC-1 are also invasive and express relatively 
high levels of miR-19 (Figure 8F). Treatment of these lines 
with miR-19 antagomirs reduced their invasive capacity 
in a transwell assay without affecting their migration 
ability (Figure 8D, 8E). Furthermore, treatment with 
miR-19 antagomirs was sufficient to reduce the number 
of invadopodia rosettes formed in KPC cells (Figure 8G, 
Supplementary Figure 10) and also decreased the gelatin 
degradation capacity of these cell lines (Figure 8H, 
Supplementary Figure 11). These data demonstrate that 
miR-19 miRNAs regulate PDAC cell invasion.
DISCUSSION 
Given its rate of mutational activation in PDAC 
and past observations of oncogene addiction, KRAS and 
components of its downstream signaling pathways represent 
robust therapeutic targets in this devastating malignancy. 
To date, efforts to directly inhibit KRAS function have 
been unsuccessful [8]; thus efforts in the field have turned 
to targeting key downstream pathways [9–11]. However, 
a deeper understanding of the mechanisms responsible 
for the transforming effect of KRAS could inform more 
effective therapeutic strategies. Several microRNAs, 
including those in the mir-17~92 cluster, display increased 
expression in PDAC as well as precursor PanIN lesions 
[22–24], suggesting that these miRNAs may play a role in 
tumorigenesis. However, to date, the functional importance 
of these miRNAs has not been evaluated in vivo.
Here we report that deletion of the mir-17~92 
miRNA cluster results in the regression of KRASG12D-
driven PanIN lesions and the expansion of normal acinar 
tissue in place of neoplastic cells over time. In addition, 
we observe that mir-17~92-null PanIN lesions have 
reduced ERK phosphorylation, and PanIN cell lines with 
ectopic mir-17~92 expression display elevated p-ERK 
levels. However, mir-17~92-null PanIN lesions display no 
changes in MEK phosphorylation or PI3K/AKT signaling, 
suggesting a specific impact of mir-17~92 on ERK 
activation. Importantly, apoptotic rates are not increased 
in mir-17~92-null PanINs, suggesting that these lesions 
are not lost by apoptosis. Moreover, the proliferation rate 
is unchanged in the adjacent acinar tissue of 17KC mice 
compared to that of KC mice, indicating that exocrine 
recovery is not due to the expansion of residual acinar 
cells in these animals. Together, these findings suggest that 
mir-17~92 loss promotes the redifferentiation of PanINs 
into acinar cells. While sophisticated lineage tracing 
experiments will be required to validate this hypothesis, 
our data are in agreement with recently published data 
demonstrating that ERK pathway activity downstream 
of KRASG12D is critical for PanIN maintenance, and 
loss of ERK signaling triggers PanIN regression into 
normally differentiated exocrine tissue [45]. Importantly, 
the effects of miRNAs on signaling pathway output are 
generally smaller in magnitude than those observed with 
small molecule inhibitors, which potentially explains the 
extended timeline of PanIN regression in 17KC mice 
compared to the rapid regression described by Collins, 
et al. using MEK inhibitors [45].
The mechanisms underlying the regulation of ERK 
activity by mir-17~92 are unknown. We explored the 
possibility that mir-17~92 increases ERK activation via 
suppression of dual-specificity phosphatases (DUSPs), 
which are well-known regulators of numerous MAPK 
family proteins, including ERK [57]. In particular, 
DUSP2, DUSP7 and DUSP10 suppress ERK activity 
and are demonstrated or predicted targets of mir-17~92 
miRNAs [48, 58–60]. Interestingly, a recent publication 
linked miR-92 and DUSP10 to PDAC cell proliferation 
in vitro, suggesting that there may indeed be an important 
role for this regulatory axis in pancreatic tumorigenesis 
[61]. However, immunohistochemical staining of DUSP2, 
DUSP7 and DUSP10 failed to demonstrate any difference 
between KC and 17KC PanIN lesions, and modulation 
of mir-17~92 levels in PanIN cell lines also failed to 
change the levels of these phosphatases. Thus, the precise 
mechanisms through which mir-17~92 regulates ERK 
phosphorylation remain unknown. Additional studies 
using inducible expression or repression of mir-17~92 
miRNAs, coupled to mRNA and proteomic profiling 
approaches, will aid in elucidating the mechanisms by 
which this cluster regulates ERK phosphorylation in the 
early stages of pancreatic tumorigenesis.
We observed similar overall survival, rates of 
metastasis, and histological prevalence of invasion at 
sacrifice between KPC and 17KPC mice, suggesting that 
Trp53 loss can compensate for mir-17~92 deletion. In the 
KPC model, mice typically develop aggressive PDAC, 
characterized by local invasion, obstructive symptoms 
involving the gastrointestinal or biliary systems, and 
metastasis, which we observe in the KPC animals of this 
study. In contrast, we find that 17KPC mice exhibit less 
aggressive primary disease, as demonstrated by longer 
survival with larger primary tumors in the absence of 
metastases, and the absence of obstructive gastrointestinal 
or biliary symptoms. These data suggest that mir-17~92 
plays a role in PDAC invasiveness. However, we cannot 
exclude the possibility that the absence of obstructive 
disease in the 17KPC mice reflects a difference in the 
initial anatomical site of these primary tumors compared 
to KPC tumors. Perhaps the tumors in 17KPC mice arise 
in the tail of the pancreas, allowing them to reach greater 
size before obstructing the duodenum or bile duct; whereas 
tumors occurring in KPC animals predominantly occur 
in the head of the pancreas, predisposing those animals 
to early obstructive phenomena.  Additional studies 
analyzing tumors at earlier stages and smaller sizes will 
be needed in order to clarify whether KPC and 17KPC 
tumors arise in different locations within the pancreas.
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Figure 8: PDAC cell line invasion and invadopodia formation is suppressed by miR-19 antagomirs. (A) Transwell invasion 
through Matrigel of KPC cell lines treated with control or miR-19-targeting antagomirs at the indicated concentrations. (B) Transwell 
migration activity of the cell lines shown in (A). (C) Quantitative RT-PCR measurement of baseline mature miR-19 levels in KPC cell lines. 
(D) Transwell invasion through Matrigel of the human PDAC cell lines MIA Paca-2 and PANC-1 treated with control or miR-19-targeting 
antagomirs at the indicated concentrations. (E) Transwell migration of activity of the cell lines shown in (D). (F) Quantitative RT-PCR 
measurement of baseline mature miR-19 levels in MIA Paca-2 and PANC-1 cells; miR-19 levels in the KPC cell line 9415#2 are shown for 
comparison. Invadopodia rosette formation (G) and FITC-gelatin degradation (H) in the KPC cell lines 9910#1 and 9248#1 treated with 
control or miR-19-targeting antagomirs. n = 3 for each cell line. p values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001. (A–F) Error 
bars represent standard deviation from the mean. (G, H) Error bars represent standard error of the mean.
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Analysis of a panel of tumor-derived cell lines 
demonstrated that 17KPC cells are specifically defective 
in their ability to form invadopodia rosettes and invade 
through Matrigel in a transwell assay, providing a potential 
link to our in vivo observations. Using antagomirs against 
miR-19, we demonstrated that miR-19 family miRNAs 
are key drivers of invadopodia formation and the invasive 
capacity of human and murine pancreatic cancer cells. 
Thus, we have identified a novel role for miR-19 in 
pancreatic cancer cells. In fact, few studies exist that 
link miR-19 to cancer cell invasion in any tumor type 
[36, 37]. Future studies will be required to validate the 
significance of miR-19 family miRNAs in the invasive 
phenotype of PDAC in vivo. In addition, expression 
profiling and proteomic studies will be required to identify 
the mechanisms through which miR-19 miRNAs regulate 
invadopodia formation and function. TIMP2, CST3, 
and TGM2 are all predicted targets of miR-19 that are 
also suppressors of invasion [37, 39, 62, 63] and could 
potentially explain the reduced invasiveness of 17KPC 
cell lines. Indeed, TGM2 is linked to miR-19-mediated 
invasion in colorectal cancer cells [37]. However, 
immunoblotting and qRT-PCR experiments failed to detect 
any difference in expression between KPC and 17KPC 
cell lines (data not shown). Matrix metalloproteinases are 
also key drivers of invasion [64], and a survey of MMP-
2, -7, -9, and MT1-MMP by qRT-PCR demonstrated no 
difference between KPC and 17KPC cell lines (data not 
shown). Given that our data point to a major effect of 
miR-19 on invadopodia formation and/or stability, and 
since none of the above factors are known to influence 
invadopodia, these negative findings are perhaps not 
surprising. Instead, they highlight the importance of the 
unbiased approaches stated above for elucidating the 
mechanisms responsible for the observed phenotypes. 
Importantly, our experiments do not preclude 
significant roles for the other miRNAs encoded within 
the mir-17~92 cluster in PDAC invasion. Indeed, other 
members of the cluster are computationally predicted to 
regulate genes previously implicated in cellular invasion. 
Thus, studies that confirm or exclude roles for these 
miRNAs in PDAC invasion will also be of importance.
Our studies reported here are potentially in conflict 
with the recently published work of Heeschen and 
colleagues [65, 66]. In their work, the authors report that 
ectopic mir-17~92 expression promotes the proliferation 
of pancreatic cancer stem cells, resulting in their premature 
depletion and consequent reduced cell transformation 
and tumorigenicity. In contrast, our studies demonstrate 
that ectopic mir-17~92 increases MEK/ERK signaling, a 
feature required for the maintenance of established PanIN 
lesions [6, 67], suggesting that elevated mir-17~92 levels 
should enhance pancreatic cancer development. However, 
we have not evaluated the self-renewal capacity of mir-
17~92 expressing PanIN cell lines, nor have we tested 
their tumorigenic capacity upon implantation into recipient 
mice. Future experiments in genetically engineered PDAC 
mouse models with enhanced mir-17~92 expression may 
be required to resolve this discrepancy.
Together, our findings demonstrate important roles 
for mir-17~92-encoded miRNAs during early stages of 
pancreatic tumorigenesis, as well as tumor progression 
and invasion. These findings provide functional support 
for the observed elevated expression of these miRNAs 
in precursor PanIN lesions and invasive PDAC. Further 
dissection of the cluster to identify the roles played by 
individual miRNAs during PanIN maintenance and PDAC 
invasion will be required in order to identify the critical 
target genes and pathways regulated by this miRNA 
cluster during pancreatic tumorigenesis.
MATERIALS AND METHODS
Animal studies
 The Ptf1a-Cre [40], mir-17~92flox [41], LSL-
KrasG12D [44], and Trp53flox [68] mouse strains have been 
described previously. Health status of all animals was 
monitored at least three times per week, and animals 
were euthanized when they displayed signs of distress or 
high tumor burden. Animals were maintained in specific 
pathogen-free facilities with abundant food and water. 
Mice were randomly assigned to the studies.  Group sizes 
were estimated based on investigators’ prior experience. 
Euthanized mice that did not have pancreatic tumors were 
censored from the analysis. Mice of both genders were 
used in all studies. The pathologist was blinded to mouse 
genotypes for quantification of histopathologic lesions. All 
animal experiments were reviewed and approved by the 
University of Massachusetts Medical School Institutional 
Animal Care and Use Committee.
Histological stains
Tissues were fixed in 10% neutral-buffered 
formalin. Five-micrometer sections on charged glass 
slides were cleared through Xylenes (Fisher #X3P) to 
100% ethanol and rehydrated through a graded alcohol 
series to distilled water. Immunostaining was performed 
as previously described [69]. A list of all antibodies used 
for immunohistochemical stains appears in Supplementary 
Table 2. Stains were developed using ABC (Vector Labs 
#PK-6101) and Nova Red (Vector Labs #SK-4800) kits 
according to manufacturer’s instructions.
Hematoxylin and eosin stains were performed 
according to field standards, and the quadchrome stain 
(consisting of a hybrid protocol derived from Sirius Red 
staining for collagen and Alcian Blue staining for mucin) 
was performed as recently described [47]. 
A licensed pathologist who was blinded to tissue 
genotypes performed quantification of tissue areas. Four 
images were quantified per section representing 1) the area 
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of greatest neoplastic progression, 2) the area of lowest 
neoplastic progression, and 3,4) areas of the pancreas that 
were consistent with the average progression for that tissue 
section. Acini, ducts, PanINs, ADM lesions, and stromal 
tissue not including blood vessels were manually outlined 
using ImageJ software and are graphed as the percentage 
area of all areas quantified. 
Cell culture experiments
All cell lines were maintained at subconfluent 
densities in high glucose DMEM (Life Technologies 
#11965) supplemented with 10% fetal bovine serum 
(Atlanta Biologicals #S11150) and 100U/ml penicillin/
streptomycin (Pen/Strep: Life Technologies #15140) (herein 
‘complete media’). Murine PDAC cell lines were generated 
in the Lewis lab. Murine PanIN cell lines were obtained 
from Nabeel Bardeesy (Massachusetts General Hospital). 
Human PDAC cell lines were obtained from ATCC, 
except for the Pa01c through Pa18C cell lines, which were 
obtained from Bert Vogelstein (Johns Hopkins University) 
[70]. Migration and invasion assays were performed as 
previously described using 8-micrometer-porous transwell 
inserts (Fisher #08-774-162) and Matrigel-coated inserts 
(Fisher #08-774-122) [71]. The invasion index was 
calculated as previously described [71]. Soft agar colony 
formation assays were performed as previously described 
[69]. Proliferation assays of adherent, subconfluent cells 
were performed by direct live cell counting after trypsin-
mediated resuspension using trypan blue exclusion over a 
period of 48 hours. Counts were plotted as the log
2
 of the 
cell number over time, and the proliferative rate of each line 
was calculated as the inverse slope of a linear regression to 
the data (i.e. time/doubling). Data shown are the average 
of greater than four experiments. P-values were calculated 
using the Student’s t-test.
For antagomir experiments, miRCURY LNA Power 
Inhibitors (Exiqon #4101004-100, #4103258-100, and 
#199006-100) were transfected into 2.5 × 105 cells per 
well of a 6-well plate using Superfect (Qiagen #301305) 
according to manufacturer’s specifications at a final 
antagomir concentration of either 50 or 100 nM.
Lentiviral infection of the human PanIN cell lines 
RP2294 and AH2375 was performed using viral vectors 
generously provided by Andrea Ventura, PhD [34]. 
Invadopodia and gelatin degradation analysis
Invadopodia rosette formation analysis and FITC-
gelatin matrix degradation assays were performed as 
previously described [72]. Briefly, to visualize invadopodia 
rosette formation, cells were plated on fibronectin-coated 
slips (10μg/ml; Corning) for 24hrs, fixed, permeabilized 
and stained with anti-cortactin antibodies (1:200; Merck 
Millipore #05-180), anti-paxillin antibodies (1:200; 
Santa Cruz Biotechnology #sc-5574), TRITC-phalloidin 
(F-actin)(1:1000; Invitrogen #R415) and DAPI (nuclei) 
(1:1000; Sigma-Aldrich #D9542). A minimum of 150 cells 
per sample were scored for rosette formation, which were 
defined by cortactin and actin colocalization. n = 3. 
For FITC-gelatin degradation analysis, coverslips 
were coated with 50μg/ml poly-L-lysine (Sigma-
Aldrich #P8920) in PBS, and then incubated with 0.5% 
glutaraldehyde (Sigma-Aldrich #G6257) in PBS. The slips 
were coated with 1:40 fluorescent 488 gelatin (‘FITC-
gelatin’) (Life Technologies #G13186) diluted with 0.2% 
unlabeled gelatin (Sigma-Aldrich) in PBS for 30 min. at 
37°C. Cells were plated for 24 hours, fixed and stained as 
above. For quantitation of matrix degradation, nine random 
fields (20x objective) were imaged from each sample 
(n = 3). ImageJ software was used to threshold the cell 
area as well as areas of matrix degradation (black areas in 
FITC-gelatin) and to calculate a ratio of matrix degradation 
to cell area. Statistical analyses were performed using a 
one-way ANOVA with a Tukey correction. 
qRT-PCR
Quantitative RT-PCR for miRNAs was performed as 
previously described [73]. After RNA isolation with TRIzol 
reagent (Invitrogen #15596), genomic contaminants were 
removed using DNAse (Life Technologies #AM1907). 
DNA-free RNA was then polyadenylated (New England 
Biolabs #M0276) and subsequently reverse transcribed 
(Invitrogen #18080) using a pool of specially designed 
primers at a concentration of 50 uM to generate cDNA 
copies of polyadenylated miRNAs. A complete list of 
primer sequences appears in Supplementary Table 3. All 
subsequent steps of the cDNA synthesis were conducted 
according to kit directions. 
PCR for miRNAs was performed as follows: 1) 
denaturation at 94°C for 15 seconds, 2) annealing at 55°C 
for 30 seconds, and 3) extension at 70°C for 34 seconds, 
for a total of 40 cycles. The reverse primer for all miRNA 
reactions was the sequence of the universal tag present in 
all 12 RT primers. The forward primer for each miRNA was 
the mature miRNA sequence given by miRBase [74]. PCR 
reactions were carried out on an ABI Step One Plus machine 
in 10ul volumes using SYBR Green (VWR #95072).
C
T
 values were calculated for all miRNA PCR 
reactions at a uniform threshold of absorbance across all 
experiments and controlled to C
T
 values for the endogenous 
reference (snoRNA234 in mouse-only experiments, U6 in 
human and cross-species comparisons). The expression of 
individual miRNAs is presented as relative snoRNA234 
units in order to convert the ΔC
T
 value for each miRNA 
into a relative molar measure (calculated as 2ΔCT). 
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